As Executive Director of Regulatory Affairs, Cynthia Dillon is responsible for the global regulatory strategies for products in development and post marketing changes for the commercialized product, Anthim®. She is an experienced strategic Regulatory Affairs leader with broad pharmaceutical (drugs and biologics) experience in small, medium and large size companies such as American Cyanamid, Hoffmann La Roche and Elusys Therapeutics. Her proven ability to lead cross-functional teams comprised of internal subject matter experts and outside contractors along with her ability to analyze the regulatory environment and complex regulations has resulted in the delivery of high-quality regulatory filings and approvals of original global applications and post marketing submissions. Over the more than 35 years of pharmaceutical experience, she has held roles with increasing responsibility that began as a Research Formulator and led to Executive Director of Regulatory Affairs. The main therapeutic areas of focus included anti-infective, metabolic disease and anti-viral. Cynthia holds a B.S. in Chemistry from Montclair State University.